{ "dataset": "Open Peptide Project \u2014 Peptide Clinical Trial & Regulatory Readout Tracker", "version": "2026-10-27", "license": "CC BY 4.0 \u2014 Open Peptide Project (https://openpeptideproject.org)", "evidence_level_scale": { "A": "Phase 3 RCT, peer-reviewed", "B": "Phase 2 RCT (peer-reviewed) or Phase 3 conference abstract", "C": "Sponsor topline announcement / Phase 1-2 abstract (not peer-reviewed)", "D": "Post hoc / subgroup / observational analysis", "R": "Regulatory action (FDA, EMA, or MFDS approval, filing, or CRL)" }, "count": 40, "events": [ { "event_id": "R01", "compound": "Retatrutide", "library_slug": "retatrutide", "sponsor": "Eli Lilly", "trial_ids": "NCT05929079 (TRIUMPH-2)", "phase": "3", "indication": "Obesity/overweight with type 2 diabetes", "what_is_measured": "% body-weight change at week 80 (two higher dose arms vs placebo)", "expected_readout_or_date": "2026-09-29 (Lancet online + Lilly press release)", "date_source_type": "peer-reviewed + sponsor press release", "status": "Reported", "sources": "https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01861-1/ | https://pubmed.ncbi.nlm.nih.gov/42810372/ | https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-substantial-weight | https://clinicaltrials.gov/study/NCT05929079" }, { "event_id": "R02", "compound": "Retatrutide", "library_slug": "retatrutide", "sponsor": "Eli Lilly", "trial_ids": "NCT05929066 (TRIUMPH-1)", "phase": "3", "indication": "Obesity/overweight without diabetes", "what_is_measured": "% body-weight change at week 80", "expected_readout_or_date": "2026-09-29 (NEJM full publication; topline was announced earlier in 2026)", "date_source_type": "peer-reviewed", "status": "Reported", "sources": "https://pubmed.ncbi.nlm.nih.gov/42814954/ | https://doi.org/10.1056/NEJMoa2604169 | https://clinicaltrials.gov/study/NCT05929066" }, { "event_id": "R03", "compound": "Retatrutide", "library_slug": "retatrutide", "sponsor": "Eli Lilly", "trial_ids": "NCT05929066, NCT05929079 (TRIUMPH-1-OSA / TRIUMPH-2-OSA substudies)", "phase": "3", "indication": "Moderate-to-severe obstructive sleep apnea with obesity/overweight", "what_is_measured": "Change in apnea-hypopnea index (AHI) at week 80", "expected_readout_or_date": "2026-10-21 (NEJM online)", "date_source_type": "peer-reviewed", "status": "Reported", "sources": "https://pubmed.ncbi.nlm.nih.gov/42904878/ | https://doi.org/10.1056/NEJMoa2611477" }, { "event_id": "R04", "compound": "Survodutide", "library_slug": "survodutide", "sponsor": "Boehringer Ingelheim (licensed from Zealand)", "trial_ids": "NCT06066528 (SYNCHRONIZE-2)", "phase": "3", "indication": "Obesity/overweight with type 2 diabetes", "what_is_measured": "Co-primary: % body-weight change and \u22655% weight loss at week 76", "expected_readout_or_date": "2026-10-01 (EASD + NEJM)", "date_source_type": "peer-reviewed + sponsor press release", "status": "Reported", "sources": "https://pubmed.ncbi.nlm.nih.gov/42820639/ | https://doi.org/10.1056/NEJMoa2607219 | https://www.globenewswire.com/news-release/2026/10/01/3372564/0/en/boehringer-ingelheim-s-survodutide-achieves-up-to-13-1-weight-loss-in-new-phase-iii-trial-alongside-significant-improvements-in-glycemic-control-in-people-with-obesity-and-type-2-d.html | https://clinicaltrials.gov/study/NCT06066528" }, { "event_id": "R05", "compound": "Petrelintide", "library_slug": "petrelintide", "sponsor": "Zealand Pharma / Roche", "trial_ids": "NCT06926842 (ZUPREME-2)", "phase": "2b", "indication": "Overweight/obesity with type 2 diabetes", "what_is_measured": "% body-weight change at week 28", "expected_readout_or_date": "2026-10-07 topline; full data 'at an upcoming scientific conference' (date unknown)", "date_source_type": "sponsor press release (topline only, not peer-reviewed)", "status": "Reported (topline)", "sources": "https://rss.globenewswire.com/news-release/2026/10/07/3376750/0/en/zealand-pharma-announces-positive-phase-2-zupreme-2-topline-results-for-amylin-analog-petrelintide-in-people-with-overweight-or-obesity-and-type-2-diabetes.html | https://clinicaltrials.gov/study/NCT06926842" }, { "event_id": "R06", "compound": "Petrelintide", "library_slug": "petrelintide", "sponsor": "Zealand Pharma", "trial_ids": "NCT06662539 (ZUPREME-1)", "phase": "2", "indication": "Obesity/overweight without diabetes", "what_is_measured": "% body-weight change at week 28 (42-week trial)", "expected_readout_or_date": "2026-09-29 (Lancet Diabetes Endocrinol online)", "date_source_type": "peer-reviewed", "status": "Reported", "sources": "https://pubmed.ncbi.nlm.nih.gov/42810355/ | https://doi.org/10.1016/S2213-8587(26)00213-5" }, { "event_id": "R07", "compound": "Efpeglenatide", "library_slug": "efpeglenatide", "sponsor": "Hanmi Pharmaceutical", "trial_ids": "Korean phase 3 (448 participants, 40-week interim topline per Hanmi); registry ID not confirmed in this pass", "phase": "3 \u2192 approval", "indication": "Chronic weight management (Korea)", "what_is_measured": "Regulatory decision: Korea MFDS marketing authorisation", "expected_readout_or_date": "2026-10-07 (MFDS approval)", "date_source_type": "sponsor press release + KRX disclosure", "status": "Approved (Korea)", "sources": "https://www.hanmi.co.kr/about/news-media/press/detail-5083.hm | https://kind.krx.co.kr/external/2026/10/07/000667/20261007001565/92008.htm" }, { "event_id": "R08", "compound": "Icotrokinra", "library_slug": "icotrokinra", "sponsor": "Johnson & Johnson", "trial_ids": "NCT06878404 (ICONIC-PsA 1)", "phase": "3", "indication": "Active psoriatic arthritis, biologic-naive (not an approved use)", "what_is_measured": "ACR20 at week 16", "expected_readout_or_date": "2026-10-20 abstract published; poster LB session 2026-11-10 (ACR Convergence)", "date_source_type": "conference abstract + sponsor press release", "status": "Reported (abstract); presentation upcoming", "sources": "https://acrabstracts.org/abstract/icotrokinra-an-il-23-receptor-targeted-oral-peptide-in-biologic-naive-participants-with-active-psoriatic-arthritis-results-through-week-24-of-a-phase-3-randomized-double-blind-placebo-controlled/ | https://www.jnj.com/media-center/press-releases/johnson-johnson-showcases-breadth-of-rheumatology-innovation-at-acr-convergence-2026-with-43-presentations-including-late-breaking-data-on-icotyde-icotrokinra-in-psoriatic-arthritis | https://clinicaltrials.gov/study/NCT06878404" }, { "event_id": "R09", "compound": "CagriSema (cagrilintide + semaglutide)", "library_slug": "cagrisema", "sponsor": "Novo Nordisk", "trial_ids": "REDEFINE 1 (post hoc analyses in women)", "phase": "3 (post hoc)", "indication": "Obesity/overweight, women by menopause stage", "what_is_measured": "% body-weight change at week 68 (post hoc, efficacy estimand)", "expected_readout_or_date": "2026-10-20 (Menopause Society poster + Novo press release)", "date_source_type": "conference poster + sponsor press release", "status": "Reported (post hoc, hypothesis-generating)", "sources": "https://www.novonordisk-us.com/media/press-releases/cagrisema-redefine1-weight-loss-women-menopause.html" }, { "event_id": "R10", "compound": "Enicepatide (CT-388)", "library_slug": "ct-388", "sponsor": "Roche (Carmot)", "trial_ids": "NCT06628362 (CT-388-104)", "phase": "2", "indication": "Type 2 diabetes with overweight/obesity", "what_is_measured": "HbA1c and % body-weight change (Roche: week 48; registry lists week 36 \u2014 discrepancy)", "expected_readout_or_date": "2026-09-22 topline", "date_source_type": "sponsor press release (topline)", "status": "Reported (topline)", "sources": "https://www.roche.com/media/releases/med-cor-2026-09-22 | https://clinicaltrials.gov/study/NCT06628362" }, { "event_id": "U01", "compound": "CagriSema (cagrilintide + semaglutide)", "library_slug": "cagrisema", "sponsor": "Novo Nordisk", "trial_ids": "REDEFINE program (NDA filed Dec 2025)", "phase": "NDA", "indication": "Chronic weight management", "what_is_measured": "FDA decision on NDA", "expected_readout_or_date": "Q4 2026 (exact PDUFA date not public)", "date_source_type": "sponsor guidance", "status": "Awaiting regulatory decision", "sources": "https://www.novonordisk-us.com/media/press-releases/cagrisema-redefine1-weight-loss-women-menopause.html | https://www.novonordisk-us.com/media/press-releases/novo-nordisk-cagrisema-fda-nda-submission.html | https://www.novonordisk.com/content/dam/nncorp/global/en/investors/pdfs/financial-results/2026/Q2-2026-Full%20presentation.pdf" }, { "event_id": "U02", "compound": "Glepaglutide (Zeydovio)", "library_slug": "glepaglutide", "sponsor": "Zealand Pharma", "trial_ids": "EASE program (EU MAA)", "phase": "MAA", "indication": "Short bowel syndrome, adults (EU)", "what_is_measured": "European Commission decision after positive CHMP opinion (17 Sep 2026)", "expected_readout_or_date": "~2026-11-23 (estimate: EC decisions are 'normally' issued 67 days after CHMP opinion)", "date_source_type": "estimate from EMA standard timeline", "status": "Awaiting regulatory decision", "sources": "https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-zeydovio_en.pdf | https://www.zealandpharma.com/media/gfdbqawp/zealand-pharma-h1-2026-interim-report.pdf" }, { "event_id": "U03", "compound": "Semaglutide (higher-dose oral Ozempic tablets)", "library_slug": "semaglutide", "sponsor": "Novo Nordisk", "trial_ids": "Supplemental application (T2D)", "phase": "sNDA", "indication": "Type 2 diabetes (higher oral dose)", "what_is_measured": "FDA decision on supplemental application", "expected_readout_or_date": "By end of 2026 (no public PDUFA date)", "date_source_type": "sponsor guidance", "status": "Awaiting regulatory decision", "sources": "https://www.novonordisk-us.com/media/press-releases/fda-approves-ozempic-pill-tablets.html | https://www.novonordisk.com/content/dam/nncorp/global/en/investors/pdfs/financial-results/2026/Q2-2026-Full%20presentation.pdf" }, { "event_id": "U04", "compound": "Vosoritide (Voxzogo)", "library_slug": "vosoritide", "sponsor": "BioMarin", "trial_ids": "Studies 111-205, 111-208, 111-302 (long-term data)", "phase": "sNDA", "indication": "Achondroplasia \u2014 conversion from accelerated to full approval", "what_is_measured": "FDA action on sNDA", "expected_readout_or_date": "2027-02-28 (PDUFA target action date)", "date_source_type": "PDUFA date announced by sponsor", "status": "Awaiting regulatory decision", "sources": "https://www.biomarin.com/news/press-releases/u-s-food-and-drug-administration-accepts-biomarins-supplemental-new-drug-application-for-full-approval-of-voxzogo-vosoritide-for-children-with-achondroplasia/" }, { "event_id": "U05", "compound": "Vosoritide (Voxzogo)", "library_slug": "vosoritide", "sponsor": "BioMarin", "trial_ids": "NCT06455059 (CANOPY-HCH-3)", "phase": "sNDA", "indication": "Hypochondroplasia (not approved anywhere)", "what_is_measured": "FDA review of sNDA submitted ~Sep 2026", "expected_readout_or_date": "unknown (no PDUFA date published by sponsor; sponsor cites 'potential 2027 launch')", "date_source_type": "unknown", "status": "Under review (filing acceptance not yet announced)", "sources": "https://www.biomarin.com/news/press-releases/biomarin-announces-positive-results-of-phase-3-voxzogo-vosoritide-study-in-hypochondroplasia-published-in-nejm-evidence/ | https://clinicaltrials.gov/study/NCT06455059" }, { "event_id": "U06", "compound": "Avexitide", "library_slug": "avexitide", "sponsor": "Amylyx", "trial_ids": "NCT06747468 (LUCIDITY)", "phase": "NDA planned", "indication": "Post-bariatric hypoglycemia", "what_is_measured": "NDA submission to FDA", "expected_readout_or_date": "By end of 2026", "date_source_type": "sponsor guidance", "status": "Filing planned", "sources": "https://www.amylyx.com/pipeline | https://clinicaltrials.gov/study/NCT06747468" }, { "event_id": "U07", "compound": "Dasiglucagon", "library_slug": "dasiglucagon", "sponsor": "Zealand Pharma", "trial_ids": "Phase 3 CHI program (NDA resubmission)", "phase": "NDA resubmission planned", "indication": "Congenital hyperinsulinism", "what_is_measured": "NDA resubmission to FDA (3-week and >3-week use)", "expected_readout_or_date": "H2 2026", "date_source_type": "sponsor guidance", "status": "Filing planned", "sources": "https://www.zealandpharma.com/media/gfdbqawp/zealand-pharma-h1-2026-interim-report.pdf" }, { "event_id": "U08", "compound": "Retatrutide", "library_slug": "retatrutide", "sponsor": "Eli Lilly", "trial_ids": "TRIUMPH program", "phase": "BLA planned", "indication": "Obesity (incl. with T2D)", "what_is_measured": "BLA submission to FDA", "expected_readout_or_date": "Q1 2027", "date_source_type": "sponsor guidance", "status": "Filing planned", "sources": "https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-substantial-weight" }, { "event_id": "U09", "compound": "Orforglipron (Foundayo)", "library_slug": "orforglipron", "sponsor": "Eli Lilly", "trial_ids": "ACHIEVE program", "phase": "NDA (new indication)", "indication": "Type 2 diabetes (approved in US for weight management only)", "what_is_measured": "FDA decision", "expected_readout_or_date": "unknown (filed Q2 2026 per Lilly Q2 update; no decision date public)", "date_source_type": "unknown", "status": "Under review", "sources": "https://www.navlindaily.com/article/31506/lilly-files-orforglipron-for-diabetes-in-u-s-japan" }, { "event_id": "U10", "compound": "Apitegromab (Isembyld)", "library_slug": "apitegromab", "sponsor": "Scholar Rock", "trial_ids": "SAPPHIRE (EU MAA resubmitted 2026-10-08)", "phase": "MAA", "indication": "Spinal muscular atrophy (EU)", "what_is_measured": "CHMP opinion", "expected_readout_or_date": "H1 2027", "date_source_type": "sponsor guidance", "status": "Awaiting regulatory decision", "sources": "https://www.nasdaq.com/press-release/scholar-rock-resubmits-apitegromab-marketing-authorisation-application-maa-european | https://investors.scholarrock.com/news-releases/news-release-details/scholar-rock-provides-update-global-apitegromab-regulatory/" }, { "event_id": "U11", "compound": "Survodutide", "library_slug": "survodutide", "sponsor": "Boehringer Ingelheim", "trial_ids": "NCT06077864 (SYNCHRONIZE-CVOT)", "phase": "3", "indication": "Overweight/obesity with CV disease, CKD or CV risk factors", "what_is_measured": "Time to first adjudicated composite CV event (CV safety)", "expected_readout_or_date": "'Later this year' (2026); registry primary completion 2026-06-01 (actual)", "date_source_type": "sponsor guidance", "status": "Upcoming readout", "sources": "https://www.globenewswire.com/news-release/2026/10/01/3372564/0/en/boehringer-ingelheim-s-survodutide-achieves-up-to-13-1-weight-loss-in-new-phase-iii-trial-alongside-significant-improvements-in-glycemic-control-in-people-with-obesity-and-type-2-d.html | https://clinicaltrials.gov/study/NCT06077864" }, { "event_id": "U12", "compound": "Efruxifermin", "library_slug": "efruxifermin", "sponsor": "Novo Nordisk (via Akero)", "trial_ids": "NCT06161571 (SYNCHRONY Real-World)", "phase": "3", "indication": "MASH/MASLD F1\u2013F4 (non-invasively diagnosed)", "what_is_measured": "Safety and tolerability over 52 weeks", "expected_readout_or_date": "Q4 2026", "date_source_type": "sponsor guidance", "status": "Upcoming readout", "sources": "https://www.novonordisk.com/content/dam/nncorp/global/en/investors/pdfs/financial-results/2026/Q2-2026-Full%20presentation.pdf | https://clinicaltrials.gov/study/NCT06161571" }, { "event_id": "U13", "compound": "Taldefgrobep alfa", "library_slug": "taldefgrobep-alfa", "sponsor": "Biohaven", "trial_ids": "NCT07281495", "phase": "2", "indication": "Overweight/obesity", "what_is_measured": "% body-weight change at week 24 (plus body-composition goals per sponsor)", "expected_readout_or_date": "2H 2026", "date_source_type": "sponsor guidance", "status": "Upcoming readout", "sources": "https://www.sec.gov/Archives/edgar/data/1935979/000193597926000067/a2026q2bhvnearningsprex991.htm | https://clinicaltrials.gov/study/NCT07281495" }, { "event_id": "U14", "compound": "Efruxifermin", "library_slug": "efruxifermin", "sponsor": "Novo Nordisk (via Akero)", "trial_ids": "NCT06215716 (SYNCHRONY Histology)", "phase": "3", "indication": "MASH, fibrosis F2\u2013F3", "what_is_measured": "Week-52 fibrosis improvement + MASH resolution (cohort 1); event-free survival at 240 weeks", "expected_readout_or_date": "unknown (pre-acquisition Akero guidance of 1H 2027 not reconfirmed by Novo; registry primary completion 2033-02 est.)", "date_source_type": "unknown", "status": "Ongoing", "sources": "https://clinicaltrials.gov/study/NCT06215716 | https://www.novonordisk.com/content/dam/nncorp/global/en/investors/pdfs/financial-results/2026/Q2-2026-Full%20presentation.pdf" }, { "event_id": "U15", "compound": "Retatrutide", "library_slug": "retatrutide", "sponsor": "Eli Lilly", "trial_ids": "NCT06662383 (TRIUMPH-5)", "phase": "3", "indication": "Obesity \u2014 head-to-head vs tirzepatide", "what_is_measured": "% body-weight change at week 80", "expected_readout_or_date": "2026-11 (est. primary completion)", "date_source_type": "CT.gov registry estimate (data collection end; public readout timing unknown)", "status": "Upcoming primary completion", "sources": "https://clinicaltrials.gov/study/NCT06662383" }, { "event_id": "U16", "compound": "Retatrutide", "library_slug": "retatrutide", "sponsor": "Eli Lilly", "trial_ids": "NCT06297603 (TRANSCEND-T2D-3)", "phase": "3", "indication": "Type 2 diabetes with moderate/severe renal impairment", "what_is_measured": "HbA1c change at week 52", "expected_readout_or_date": "2026-10 (est. primary completion)", "date_source_type": "CT.gov registry estimate (data collection end; public readout timing unknown)", "status": "Upcoming primary completion (Registry status: Active, not recruiting; last updated 2026-07-20 \u2014 estimate not revised since July, so date may slip; no readout announced yet)", "sources": "https://clinicaltrials.gov/study/NCT06297603" }, { "event_id": "U17", "compound": "Tirzepatide", "library_slug": "tirzepatide", "sponsor": "Eli Lilly", "trial_ids": "NCT06914895 (SURPASS-T1D-1)", "phase": "3", "indication": "Type 1 diabetes with obesity/overweight", "what_is_measured": "HbA1c change at week 40", "expected_readout_or_date": "2026-11 (est. primary completion)", "date_source_type": "CT.gov registry estimate (data collection end; public readout timing unknown)", "status": "Upcoming primary completion", "sources": "https://clinicaltrials.gov/study/NCT06914895" }, { "event_id": "U18", "compound": "Tirzepatide", "library_slug": "tirzepatide", "sponsor": "Eli Lilly", "trial_ids": "NCT06962280 (SURPASS-T1D-2)", "phase": "3", "indication": "Type 1 diabetes with obesity/overweight (long-term)", "what_is_measured": "HbA1c change at week 40", "expected_readout_or_date": "2026-11 (est. primary completion)", "date_source_type": "CT.gov registry estimate (data collection end; public readout timing unknown)", "status": "Upcoming primary completion", "sources": "https://clinicaltrials.gov/study/NCT06962280" }, { "event_id": "U19", "compound": "MariTide (maridebart cafraglutide)", "library_slug": "maritide", "sponsor": "Amgen", "trial_ids": "NCT06858839 (MARITIME-1)", "phase": "3", "indication": "Obesity/overweight without T2D", "what_is_measured": "% body-weight change at week 72", "expected_readout_or_date": "2027-01-21 (est. primary completion)", "date_source_type": "CT.gov registry estimate (data collection end; public readout timing unknown)", "status": "Upcoming primary completion", "sources": "https://clinicaltrials.gov/study/NCT06858839" }, { "event_id": "U20", "compound": "MariTide (maridebart cafraglutide)", "library_slug": "maritide", "sponsor": "Amgen", "trial_ids": "NCT06858878 (MARITIME-2)", "phase": "3", "indication": "Obesity/overweight with T2D", "what_is_measured": "% body-weight change at week 72", "expected_readout_or_date": "2027-01-21 (est. primary completion)", "date_source_type": "CT.gov registry estimate (data collection end; public readout timing unknown)", "status": "Upcoming primary completion", "sources": "https://clinicaltrials.gov/study/NCT06858878" }, { "event_id": "U21", "compound": "Mazdutide", "library_slug": "mazdutide", "sponsor": "Innovent Biologics", "trial_ids": "NCT06884293", "phase": "3", "indication": "Overweight/obesity with MASLD (China), vs semaglutide", "what_is_measured": "% body-weight change and liver-fat change at week 48", "expected_readout_or_date": "2026-12-31 (est. primary completion)", "date_source_type": "CT.gov registry estimate (data collection end; public readout timing unknown)", "status": "Upcoming primary completion", "sources": "https://clinicaltrials.gov/study/NCT06884293" }, { "event_id": "U22", "compound": "CagriSema (cagrilintide + semaglutide)", "library_slug": "cagrisema", "sponsor": "Novo Nordisk", "trial_ids": "NCT07011667", "phase": "3", "indication": "Obesity \u2014 weight loss and maintenance", "what_is_measured": "Relative body-weight change, week 0 to 80", "expected_readout_or_date": "2027-03-01 (est. primary completion)", "date_source_type": "CT.gov registry estimate (data collection end; public readout timing unknown)", "status": "Upcoming primary completion", "sources": "https://clinicaltrials.gov/study/NCT07011667" }, { "event_id": "U23", "compound": "Icotrokinra", "library_slug": "icotrokinra", "sponsor": "Johnson & Johnson", "trial_ids": "NCT06807424 (ICONIC-PsA 2)", "phase": "3", "indication": "Active psoriatic arthritis (biologic-experienced and naive)", "what_is_measured": "ACR20 at week 16", "expected_readout_or_date": "2027-02-10 (est. primary completion)", "date_source_type": "CT.gov registry estimate (data collection end; public readout timing unknown)", "status": "Upcoming primary completion", "sources": "https://clinicaltrials.gov/study/NCT06807424" }, { "event_id": "U24", "compound": "Eloralintide", "library_slug": "eloralintide", "sponsor": "Eli Lilly", "trial_ids": "NCT07215559", "phase": "2", "indication": "Obesity/overweight \u2014 eloralintide and macupatide alone or combined", "what_is_measured": "% body-weight change at week 32", "expected_readout_or_date": "2027-03 (est. primary completion)", "date_source_type": "CT.gov registry estimate (data collection end; public readout timing unknown)", "status": "Upcoming primary completion", "sources": "https://clinicaltrials.gov/study/NCT07215559" }, { "event_id": "U25", "compound": "Setmelanotide", "library_slug": "setmelanotide", "sponsor": "Rhythm Pharmaceuticals", "trial_ids": "NCT06772597", "phase": "2", "indication": "Prader-Willi syndrome", "what_is_measured": "Frequency/severity of adverse events to week 52", "expected_readout_or_date": "2026-10-31 (est. primary completion)", "date_source_type": "CT.gov registry estimate (data collection end; public readout timing unknown)", "status": "Upcoming primary completion", "sources": "https://clinicaltrials.gov/study/NCT06772597" }, { "event_id": "U26", "compound": "Setmelanotide", "library_slug": "setmelanotide", "sponsor": "Rhythm Pharmaceuticals", "trial_ids": "NCT06760546", "phase": "3", "indication": "Congenital hypothalamic obesity (substudy)", "what_is_measured": "Mean % change in BMI after 26 weeks", "expected_readout_or_date": "2027-03-13 (est. primary completion)", "date_source_type": "CT.gov registry estimate (data collection end; public readout timing unknown)", "status": "Upcoming primary completion", "sources": "https://clinicaltrials.gov/study/NCT06760546" }, { "event_id": "U27", "compound": "Octreotide (subcutaneous depot, CAM2029)", "library_slug": "octreotide", "sponsor": "Camurus", "trial_ids": "NCT05050942 (SORENTO)", "phase": "3", "indication": "Gastroenteropancreatic neuroendocrine tumours", "what_is_measured": "Progression-free survival (blinded central review)", "expected_readout_or_date": "2026-11 (est. primary completion; event-driven)", "date_source_type": "CT.gov registry estimate (data collection end; public readout timing unknown)", "status": "Upcoming primary completion", "sources": "https://clinicaltrials.gov/study/NCT05050942" }, { "event_id": "U28", "compound": "Pasireotide", "library_slug": "pasireotide", "sponsor": "Recordati", "trial_ids": "NCT05928390 (PASIPHY)", "phase": "2", "indication": "Post-bariatric hypoglycaemia", "what_is_measured": "Blood glucose during mixed-meal test at 12 weeks", "expected_readout_or_date": "2026-10-29 (est. primary completion)", "date_source_type": "CT.gov registry estimate (data collection end; public readout timing unknown)", "status": "Upcoming primary completion (Registry status: Active, not recruiting; last updated 2026-09-17)", "sources": "https://clinicaltrials.gov/study/NCT05928390" }, { "event_id": "U29", "compound": "Vosoritide (Voxzogo)", "library_slug": "vosoritide", "sponsor": "BioMarin", "trial_ids": "NCT06668805", "phase": "2", "indication": "Noonan syndrome with inadequate growth after growth hormone", "what_is_measured": "Change in annualized growth velocity at 6 months", "expected_readout_or_date": "2027-03 (est. primary completion)", "date_source_type": "CT.gov registry estimate (data collection end; public readout timing unknown)", "status": "Upcoming primary completion", "sources": "https://clinicaltrials.gov/study/NCT06668805" }, { "event_id": "U30", "compound": "Apitegromab (Isembyld)", "library_slug": "apitegromab", "sponsor": "Scholar Rock", "trial_ids": "NCT05626855 (ONYX)", "phase": "3 (extension)", "indication": "SMA types 2 and 3, long-term extension", "what_is_measured": "Long-term safety and tolerability (up to 6 years)", "expected_readout_or_date": "2026-11-01 (est. primary completion)", "date_source_type": "CT.gov registry estimate (data collection end; public readout timing unknown)", "status": "Upcoming primary completion", "sources": "https://clinicaltrials.gov/study/NCT05626855" } ] }